Compare Natera Inc. Common Stock (NTRA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Summit Therapeutics Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Summit Therapeutics Inc trades at $15.02 (market cap $12.38B). The key difference: Natera Inc. Common Stock is far larger — about 4.6× Summit Therapeutics Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| NTRA | SMMT | |
|---|---|---|
Market Cap | $57.03B | $12.38B |
Volume | 1,131,157 | 7,111,626 |
Sector | Health | Health |
52-Week High | $425.64 | $26.38 |
52-Week Low | $179.42 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $56.18B | $11.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
